BACKGROUND: It is not known whether lung cancer patients with interstitial lung disease (ILD) might have higher serum levels of KL-6, a high molecular weight glycoprotein classified as a polymorphic epithelial mucin. In addition, prognosis of these patients with elevated serum KL-6 levels might be poorer than that with normal KL-6 levels, but it has not been well clarified. METHODS: Serum KL-6 levels in 273 lung cancer patients with or without ILD, and prognostic significance of elevated serum KL-6 levels in these patients were studied using uni- and multivariate analyses. RESULTS: Serum KL-6 levels were elevated (>500 U/ml) in 73.5% of lung cancer patients with ILD and in 33.7% of those without ILD. Serum KL-6 levels in lung cancer patients with ILD were significantly higher than those without ILD. In lung cancer patients with ILD, elevated serum KL-6 has no prognostic significance, but in those without ILD, however, it was one of the unfavorable prognostic factors. CONCLUSIONS: Elevated serum KL-6 levels can be observed in lung cancer patients both with and without ILD. Having ILD has strong prognostic impact in patients with lung cancer. In those without ILD, however, elevated KL-6 levels may be related to poor prognosis. J. Clin. Lab. Anal. 24:295-299, 2010.
BACKGROUND: It is not known whether lung cancerpatients with interstitial lung disease (ILD) might have higher serum levels of KL-6, a high molecular weight glycoprotein classified as a polymorphic epithelial mucin. In addition, prognosis of these patients with elevated serum KL-6 levels might be poorer than that with normal KL-6 levels, but it has not been well clarified. METHODS: Serum KL-6 levels in 273 lung cancerpatients with or without ILD, and prognostic significance of elevated serum KL-6 levels in these patients were studied using uni- and multivariate analyses. RESULTS: Serum KL-6 levels were elevated (>500 U/ml) in 73.5% of lung cancerpatients with ILD and in 33.7% of those without ILD. Serum KL-6 levels in lung cancerpatients with ILD were significantly higher than those without ILD. In lung cancerpatients with ILD, elevated serum KL-6 has no prognostic significance, but in those without ILD, however, it was one of the unfavorable prognostic factors. CONCLUSIONS: Elevated serum KL-6 levels can be observed in lung cancerpatients both with and without ILD. Having ILD has strong prognostic impact in patients with lung cancer. In those without ILD, however, elevated KL-6 levels may be related to poor prognosis. J. Clin. Lab. Anal. 24:295-299, 2010.
Authors: Stephen G Spiro; Nichole T Tanner; Gerard A Silvestri; Sam M Janes; Eric Lim; Johan F Vansteenkiste; Robert Pirker Journal: Respirology Date: 2010-01 Impact factor: 6.424
Authors: S Fukaya; H Oshima; K Kato; Y Komatsu; H Matsumura; K Ishii; H Miyama; T Nagai; I Tanaka; A Mizutani; M Katayama; S Yoshida; K Torikai Journal: Rheumatol Int Date: 2000 Impact factor: 2.631
Authors: Marie-Christine Aubry; Jeffrey L Myers; William W Douglas; Henry D Tazelaar; Tanya L Washington Stephens; Thomas E Hartman; Claude Deschamps; V Shane Pankratz Journal: Mayo Clin Proc Date: 2002-08 Impact factor: 7.616
Authors: Rob Janssen; Hiroe Sato; Jan C Grutters; Alfred Bernard; Heleen van Velzen-Blad; Roland M du Bois; Jules M M van den Bosch Journal: Chest Date: 2003-12 Impact factor: 9.410